Article
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Cell reports - 5 Apr 2022
Rajkumar Shivshankari, Berry Diana, Heney Kayla A, Strong Colton, Ramsay LeeAnn, Lajoie Mathieu, Alkallas Rached, Nguyen Tan-Trieu, Thomson Cameron, Ahanfeshar-Adams Mozhdeh, Dankner Matthew, Petrella Teresa, Rose April A N, Siegel Peter M, Watson Ian R
Abstract excerpt
Although combination BRAF/MEK inhibition has produced significant survival benefits for BRAF p.V600 mutant melanomas, targeted therapies approved for BRAF non-p.V600 mutant melanomas remain limited. Through the analysis of 772 cutaneous melanoma exomes, we reveal that BRAF non-p.V600 mutations co-occurs more frequently with NF1 loss, but not with oncogenic NRAS mutations, than expected by chance. We present cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.